Структурный полиморфизм генов, ответственных за функциональное состояние эндотелия, и его связь с тяжестью поражения коронарных артерий у больных ишемической болезнью сердца
![Диссертация: Структурный полиморфизм генов, ответственных за функциональное состояние эндотелия, и его связь с тяжестью поражения коронарных артерий у больных ишемической болезнью сердца](https://westud.ru/work/5243776/cover.png)
Диссертация
В данной связи приобретает значение поиск дополнительных маркеров, позволяющих оценить ближайший и отдаленный прогноз заболевания. Согласно современным научным представлениям нарушение функционального состояния эндотелия сосудов — развитие его дисфункции — является основополагающим этапом в атерогенезе (Беркович О.А., 2002; Vanhoutte P.M., 1997; Drexler Н., 1999). Выраженность нарушений… Читать ещё >
Содержание
- АКТУАЛЬНОСТЬ ТЕМЫ
- ЦЕЛЬ РАБОТЫ
- ЗАДАЧИ ИССЛЕДОВАНИЯ
- НАУЧНАЯ НОВИЗНА
- ОСНОВНЫЕ ПОЛОЖЕНИЯ, ВЫНОСИМЫЕ НА ЗАЩИТУ
- ПРАКТИЧЕСКАЯ ЗНАЧИМОСТЬ РАБОТЫ
- АПРОБАЦИЯ РАБОТЫ
- СТРУКТУРА И ОБЪЕМ ДИССЕРТАЦИИ
- ГЛАВА 1. ОБЗОР ЛИТЕРАТУРЫ
- 1. 1. ПОНЯТИЕ ОБ ЭНДОТЕЛИАЛЬНОЙ ДИСФУНКЦИИ
- 1. 2. МЕСТО ДИСФУНКЦИИ ЭНДОТЕЛИЯ В ПАТОГЕНЕЗЕ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА
- 1. 3. РОЛЬ ГЕНЕТИЧЕСКИХ ФАКТОРОВ В ФУНКЦИОНИРОВАНИИ ЭНДОТЕЛИЯ
- 1. 3. 1. Структурный полиморфизм гена эндотелиальной NO синтетазы
- 1. 3. 2. Инсерционно-делеционный (I/D) полиморфизм гена ангиотензин-превращающего фермента, ИБС и функция эндотелия
- 1. 4. ВЗАИМОСВЯЗЬ УРОВНЯ ГОМОЦИСТЕИНА И ФУНКЦИОНАЛЬНОГО СОСТОЯНИЯ ЭНДОТЕЛИЯ СОСУДОВ
Список литературы
- Беленков Ю.Н., Мареев В. Ю., Агеев Ф. Т. Ингибиторы ангиотензин-превращающего фермента в лечении сердечно-сосудистых заболеваний // Издательство «ИНСАЙТ». Москва, 2001. — 128С.
- Беленков Ю.Н., Савченко А. П., Матчин Ю. Г. Современные принципы коронарной ангиографии. // Сердце. 2002. Т.1. — № 6. — С1−5.
- Бувальцев В.И. Современные методы исследования функции эндотелия в клинике. //Международный медицинский журнал. 2001. -№ 4. — С45−48
- Гланц С. Медико-биологическая статистика. М. Практика, 1998. -459 с.
- Гогин Е.Е., Груздев А. К., Лазарев И.А.и др. Варианты нестабильной стенокардии в свете современных представлений о механизмах повреждения эндотелия. // Тер. Арх.- 1999.-№ 4.-С.21−28.
- Гогин Е.Е. Гипертоническая болезнь. Москва. — 1997. 245С.
- Гогин Е.Е. Курение, эндотелий и гипертоническая болезнь // Клиническая медицина 1998. -№ 11. — С. 10−13.
- Грацианский Н.А. Предупреждение обострений коронарной болезни сердца. Вмешательства с недоказанным клиническим эффектом: ингибиторы ангиотензинпревращающего фермента и антиоксиданты // Кардиология -1998. -№ 6. С.4−17.
- Джурич Д., Стефанович Е., Тасич Н. с соавт. Применение тестов реактивности плечевой артерии при оценке дисфункции эндотелия в процессе старения // Кардиология 2000. -№ 11.- С.24−27.
- Зайнулина М.С., Петрищев Н. Н. Эндотелиальная дисфункция и ее маркеры при гестозе // Журнал акушерства и женских болезней -1997.-№ 7. С.14−16.
- Затейщиков Д. А, Минушкина Л. О, Кудряшова О. Ю. с соавт. Функциональное состояние эндотелия у больных артериальной гипертонией и ишемнческой болезнью сердца // Кардиология 2000. — № 6. -С.14−17.
- Затейщиков Д.А., Минушкина Л. О., Кудряшова О. Ю. и др. Полиморфизм генов NO-синтетазы и рецептора ангиотензина II 1 -го типа и эндотелиальный гемостаз у больных ишемнческой болезнью сердца. // Кардиология.-2000.-№ 11.-С.28−32.
- Затейщикова А.А., Затейщиков Д. А. Эндотелииальная регуляция сосудистого тонуса: методы исследования и клиническое значение // Кардиология 1998. — № 9. — С.68−80.
- И.В. Зотова, Д. А. Затейщиков, Б. А. Сидоренко. Синтез оксида азота и развитие атеросклероза. // Кардиология. 2002. — № 4. — С.58−67.
- Иванова О.В., Балахонова Т. В., Соболева Г. Н. с соавт. Состояние эндотелийзависимой вазодилатации плечевой артерии у больныхгипертонической болезнью, оцениваемое с помощью ультразвука высокого разрешения // Кардиология 1997. — № 7. — С.41−46.
- Иванова О.В., Соболева Г. Н., Карпов Ю. А. Эндотелиальная дисфункция — важный этап развития атеросклеротического поражения сосудов // Терапевтический архив 1997. — № 6. — С.78−83.
- Манухина Е.Б., Малышев И. Ю. Роль оксида азота в сердечнососудистой патологии: взгляд патофизиолога. // Российский кардиологический журнал. 2000. — № 25. — С.55−63.
- Метелица В.И. Справочник по клинической фармакологии сердечнососудистых лекарственных средств. 2-е издание. // Москва. -Издательство Бином, 2002. 563С.
- Минушкина JI.O., Затейщиков Д. А., Кудряшова О.Ю с соавт. Дисфункция эндотелия: связь с полиморфизмом гена рецептора (тип 1) ангиотензина 11 у больных ишемичесской болезнью сердца // Кардиология -2000. № 1. -С.20−24 .
- Минушкина JI.O., Затейщиков Д. А., Затейщикова А. А., Зотова И. В., Кудряшова О. Ю., Носиков В. В., Сидоренко Б. А. Полиморфизм гена эндотелиальеной NO-синтетазы и гипертрофия миокарда у больных артериальной гипертонией. // Кардиология.-2002.-№ 3.-С.30−34.
- Фомин В.В., Л.В.Козловская. С-реактивный белок и его значение в кардиологической практике. // Консилиум медикум. 2003. — № 5. -С.22−24
- Шляхто Е.В., Конради А. О. Блокирование ренин-ангиотензиновой системы при артериальной гипертензии: фармакогенетический подход. // Артериальная гипертензия. 2002. — № 3. -Том 4. — С.24−27
- Adams М, Smith PD, Martin D, Thompson JR, Lodwick D, Samani NJ. Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction. // QJM.-1996.-Vol.89.-P.437−44.
- Agerholm-Larsen B, Tybjaerg-Hansen A, Frikke-Schmidt R, Gronholdt ML, Jensen G, Nordestgaard BG. ACE gene polymorphism as a risk factor for ischemic cerebrovascular disease. // Ann Intern Med.-1997.-Vol.l27.-№ 5.-P.346−55.
- Agerholm-Larsen В., Nordestgaard B.G., Tybjasrg-Hansen A. ACE gene polymorphism in cardiovascular disease. Meta-analyses of small and large studies in whites. // Arterioscler Thromb Vase Biol. 2000- 20: 484 492.
- A1 Suwaidi J, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. // Circulation. 2000- 101:948 -954.
- Alvarez R, Gonzalez P, Batalla A, Reguero JR, Iglesias-Cubero G, Hevia S, et al. Association between the NOS3 (-786T/C) and the ACE (I/D) DNA genotypes and early coronary artery disease. // Nitric Oxide 2001−5:343−8.
- Alvarez R., Reguero J.R., Batalla A., Iglesias-Cubero G., Cortina A., Alvarez V., Coto E. Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease. // Car-diovasc. Res.1998- 40 (2) PP 375−379.
- Ambrose JA, Tannenhaum MA, Alexopoulos D et al. Angiographic progression of coronary artery disease ana the development of myocardial infarction.//J. Amer. Coll. Cardiol. 1988- 92: 657−671.
- Anderson TJ, Gerhard MD, Meredith IT, Charbonneau F, Delagrange D, Creager MA, Selwyn AP, Ganz P. Systemic nature of endothelial dysfunction in atherosclerosis. // Am J Cardiol. 1995−75:71B-74B.
- Cardiol. 1995−26:1235−1241.
- Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. // J Am Coll Cardiol. 1999−34:631−638.
- Beckman J.S., Koppenol W.H. Nitric oxide, superoxide and peroxynitrite: the good, the bad and the ugly. // Am J Physiol 1996- 271: 1424−1437.
- Bigi R, Cortigiani L, Colombo P, Desideri A, Bax JJ, Parodi O. Prognostic and clinical correlates of angiographically diffuse non-obstructive coronary lesions. // Heart. 2003−89(9): 1009−13.
- Blann AD, Tarberner DA. A reliable marker of endothelial cell disfunction: does it exist? // Brit. J. Haematol. 1995- 90: 244−248.
- Bonetti P.O., Lerman L.O., Lerman A. Endothelial Dysfunction A Marker of Atherosclerotic Risk // Arterioscler Thromb Vase Biol. 2003−23:168−175.
- Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering: are they clinically relevant? // Eur Heart J. In press.
- Boulanger C.M., Tanner F.G., Bea M.L. et al. Oxidized low density lipoproteins induce mRNA expression and release of endotelin from human and porcine endothelium. // Circulat Res 1992- 70: 1191−1197.
- Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetra-hydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis.// Circulation. 1998 Dec 8−98(23):2520−6.
- Brown BG, Zhao X, Sacco DE, Albers J J. Lipid lowering and plaque regression: new insights into the prevention of plaque disruption and clinical events in coronary disease. //Circulation. 1993−87:1781−1791.
- Casino PR, Kilcoyne CM, Quyyumi A A, Hoeg JM, Panza JA. The role ot nitric oxide in endothelium-dependent vasodilation of hypercholes-terolemic patients. //Circulation, 1993, 88: 2541−2547.
- Celermajer DS, Sorensen KE, Georgakopoulos D. Cigarette smoking is associated witn dose-related and potentially reversible iinpairement of endothelium-dependent dilation in healthy young adults. // Circulation, 1993−88:2140−2155.
- Celermajer D.S., Dollery C., Burch M. et. al. Role of endothelium in the maintenance of low pulmonary vascular tone in normal children // Circulation-1994. Vol. 89. — P.2041−2044.
- Celermajer D.S., Sorensen K.E., Gooch V.M. et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. // Lancet 1992−340:1111−1115.
- Celermajer D.S., Adams M.R., Clarcson P. Passive smoking and impaired endothelium arterial dilatation in healthy young adults // N.Engl. J. Med. 1996. -Vol.18. — 334:3. — P.150−154.
- Celermajer D. Testing endothelial function using ultrasound // J. of Car-diovasc. Pharmacol. 1998. -Vol. 32, suppl.3. — P.29−32.
- J Am Coll Cardiol. 1997−30:325−333.
- Chen C.Y. Effects of homocysteine on smooth cell proliferation in both cell culture and artery perfusion models. // J Surgical Research. 2000. -88. — P.26−23.
- Cockcroft JR, Chowienczyk PJ, Urett SE, Chen CP et al. Nebivolol vasodilated human forearm vasculature, evidence for an L-arginine/NO-dependent mccahanism. // J. Pharmacol. Exper. Ther. 1995- 274(3): 10 671 071.
- Crisan D., Carr J. Angiotensin I-converting enzyme. Genotype and disease associations. // JMD 2000- 2(3): 105−125.
- Davies M.J., Thomas A.C. Plaque fissuring the cause of acute myocardial infarction, sudden ischemic death, and creshendo angina. // Brit. Heart Journ., 1985: 53: 363−373.
- Davis SF, Yeung AC, Meridith IT et al. Early endothelial dysfunction predicts the development ottransplant coronary artery disease at I year posttransplant. // Circulation 1996- 93: 457−462.
- Drexler H. Endothelial dysfunction: clinical implications. // Prog Cardio-vasc Dis. 1997−39:287−324.
- Drexler H., Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients by L-arginine. // Lancet, 1991- 338: 1546−1550.
- Dzau V. Cell biology and genetics of angiotensin in cardiovascular disease. //J Hypertens 1994- 12: Suppl4: 3−10.
- Dzau V.J., Gibbons G.H. Endothelium and growth factors in vascular remodelling of hypertension. // Hypertension, 1991: 18 suppl. Ill: III-115-III-121.
- Egashira K, Inou T, Hirooka Y, Yamada A. et al. Evidence of impaired endothclium-dependent coronary vasodilation in patients with angina pectoris and normal coronary angiograins. //New Engl. J. Mod. 1993- 328: 1659−1664.
- Emond M, Mock MB, Davis KB, Fisher LD, Holmes DR Jr, Chaitman BR, Kaiser GC, Alderman E, Killip T 3rd. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. //Circulation. 1994−90(6):2645−57.
- Fichtlscherer S., Rosenberger G., Walter D.H. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. // Circulation. 2000- 102:1000 -1006.
- Fleming I., Busse R. Signal transduction of eNOS activation. // Cardio-vasc Res 1999- 43: 532−541.
- Fogarty D.G., Maxwell A.P., Doherty C.C. et. al. ACE gene typing. // Lancet. 1994- 343- PP 851−852.
- Furchgott R.F., Zawadszki J.V. The obligatory role of endotnelial cells in the relazation of arterial smooth muscle by acetylcholine. // Nature. 1980: 288: 373−376.
- Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. // FASEB J. 1989- 3: 2007−2018.
- Fuster V., Badimon J.J., Cjesebro J.H.The pathogenesis of coronary artery disease and the acute coronary syndrome. // N. Engl. J. Med. -1992.-Vol. 326.-P. 242−250.
- Fuster V., Lewis A. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. // Circulation, 1994: 90: 21 262 146.-11 390. Gallagher PM, Meleady R, Shields DC, Tan KS, McMaster D, Rozen R,
- Evans A, Graham IM, Whitehead AS. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. // Circulation. 1996 Nov l-94(9):2154−8.
- Garthwaite J. Glutamate, nitric oxide and cell-cell signaling in the nervous system. // Trends Neuroscience. 1991. — Vol.14. — P.60−67.
- Gayagay G, Yu B, Hambly B, Boston T, Hahn A, Celermajer DS, TrentRJ: Elite endurance athletes and the ACE I allele-the role of genes in athletic performance. // Hum Genet 1998, 103:48−50
- Geller D.A., Lowenstein C.J., Shapiro R.A. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. // Proc Natl Acad Sci USA 1993: 90: 3491−3495.
- Gibbons G.H., Dzau V.J. The emerging concept of vascular remodeling. //N Engl J Med 1994- 330: 1431−1438.
- Giroud D., Li JM, Urban P, Meier B, Rutishauer W. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. // Amer. J. Cardiol. 1992- 69: 729−732.
- Gokce N, Keaney JF Jr, Frei B, et al. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. // Circulation. 1999−99:3234 -3240.
- Graeber JE, Slott JH, Ulane RE, Schulman JD, Stuart MJ. Effect of homocysteine and homocystine on platelet and vascular arachidonic acid metabolism. // Pediatr Res. 1982−16(6):490−3.
- Griffith T.M., Edwards D.H., Lewis M.J. et al. The nature ofendothe-lium-derived relaxant factor // Nature 1984. — Vol. 308. — P.645−647.
- DrexlerH. Nitric Oxide Synthases in the Failing Human Heart: A Dou-bled-Edged Sword? // Circulation.- 1999. Vol. 99. — P.2972 — 2975
- Hacket D., Davies G., Maseri A. Pre-existing coronary stenosis in patients with first myocardial infarction are not necessary severe. // Europ. Heart J. 1988, 9: 1317−1323.
- Halcox JPJ, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KRA, Quyyumi A. Prognostic value of coronary vascular endothelial dysfunction. //Circulation. 2002−106:653−658.
- Hall A. V., Antoniou H., Wang Y. et al. Structural organization of the human neuronal nitric oxide synthase gene (NOS1). // J Biol Chem 1995- 269: 33 082−33 090.
- Hambrecht R, Wolf A, Gielen S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. // N Engl J Med. 2000−342:454 -460.
- Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. // Lancet. 1999 Jul 31−354(9176):407−13.
- Hasdai D, Gibbons RJ, Holmes DR Jr, Higano ST, Lerman A. Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. // Circulation. 1997−96:3390 -3395.
- Hasdai D, Lerman A. The assessment of endothelial function in the cardiac catheterization laboratory in patients with risk factors for atherosclerotic coronary artery disease. // Herz. 1999−24:544 -547.
- Heilzer T, Just H, Munzel T. Antioxidant vitamin С improves endothelial dysfunction in chronic smokers. // Circulation, 1996: 94: 6−9.
- Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. // Circulation. 2001−104:2673−2678.
- Heitzer T, Yla Herttuala S, Wild E, et al. Effect of vitamin E on endothelial vasodilator function in patients with hypercholesterolemia, chronic smoking or both. // J Am Coll Cardiol. 1999−33:499 -505.
- Heitzer Т., Via Herttuala S., Luoma J. et al. Cigarette smoking potentiates endothelial dislunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. // Circulation. 1996, 93: 1346−1353.
- Hingorani A.D., Liang C.F., Fatibene J. et al. A common variant of the endothelial nitric oxide synthase (Glu298-Asp) is a major risk factor for coronary artery disease in the UK.//Circulation 1999- 100: 1515−1520.
- Hingorani AD, Cross J, Kharbanda RK, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. // Circulation. 2000- 102:994 -999.
- Hingorani AD. Polymorphisms in endothelial nitric oxide synthase and atherogenesis: John French Lecture 2000. // Atherosclerosis 2001−154:521−7.
- Hutter AM Jr. Is there a left main equivalent? // Circulation. 1980 Aug-62(2):207-ll
- Iwai N., Ohmichi N., Nakamura Y., Kinoshita M. // DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy.//Circulation. 1994- 90- PP2622−2628.
- Izumi M, Iwai N, Ohmichi N, Nakamura Y, Shimoike H, Kinoshita M. Molecular variant of 5,10-methylenetetrahydrofolate reductase is a risk factor of ischemic heart disease in the Japanese population. //Atherosclerosis. 1996 Apr 5−121(2):293−4
- James K. Liao Endothelium and acute coronary syndromes //Clin. Chem., Aug 1998- 44: 1799- 1808
- Jeerooburkhan N, Jones LC, Bujac S, Cooper JA, Miller GJ, Vallance P, Humphries SE, Hingorani AD. Genetic and environmental determinantsof plasma nitrogen oxides and risk of ischemic heart disease.// Hypertension. 2001 Nov-38(5): 1054−61.
- Judkins MP. Percutaneous transfemoral selective coronary arteriography. // Radiol Clin North Am. 1968−6(3):467−92
- Kaplan N. Clinical Hypertension. // W.B. Saunders. 1995. P365.
- Kaski JC, Elliott PM, Salomone O, Dickinson K, Gordon D, Hann C, Holt DW. Concentration of circulating plasma endothelin in patients with angina and normal coronary angiograms. // Br Heart J. 1995−74(6):620−4.
- Kaski JC, Elliott PM. Angina pectoris and normal coronary arteriograms: clinical presentation and hemodynamic characteristics. // Am J Cardiol. 1995 Nov 2−76(13):35D-42D
- Kazuhiro Sase., Michel T. Expression and regulation of endothelial nitric oxide synthase. //TCM 1997- 7(1): 28−37.
- Keaney JF, Jr, Vita JA. Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. // Prog Cardio-vasc Dis. 1995−38:129−154.
- Lahiri D.K., Bye S., Nurberger J.J.Jr. et al.// J. Biol Chem and Biophys Methods. 1992- 25: 193−205.
- Langille BL. Morphologic responses of endothelium to shear stress: reorganization of the adherens junction. // Microcirculation. 2001 -8(3): 195 206.
- Lasher TF. Angiotensin, ACE-inhibitors and endothelial control of vasomotor tone. // Basic Research. Cardiol. 1993- 88(SI): 15−24.
- Lerman A, Burnett JC Jr. Intact and altered endothelium in regulation of vasomotion. // Circulation. 1992−86(suppl III):III-12-II-19.
- Levine GN, Frei B, Koulouris SN, et al. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. // Circulation. 1996−93:1107−1113.
- Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. // Circulation. 2002−105:1135−1143.
- Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. // Circulation. 2001−104:365−372.-119 147. Libby P. Molecular bases of the acute coronary syndromes. // Circulation1995−91:2844−50.
- Little WC, Constantinescu M., Applegate RG et al. Can coronary angiography predict the site of subsequent myocardial infarction in patients with mils-to-moderatecoronary disease? // Circulation 1988: 78: 11 571 166.
- Ludmer PL, Selwyn AP, Shook TL et al. Paradoxical vasoconstriction induced by acetylcholin in athero-sclerotic coronary arteries. // New Engl. J. Med. 1986,315: 1046−1051.
- Luscher T. Heterogeneity of endothelial dysfunction in hypertension // Eur. Heart 1992. -Vol. 13, suppl. D-P.50−55.
- Luscher T. The endothelium. Target and promotor of hypertension? // Hypertension 1990.-Vol. 15. — P.482−485.
- Luscher Т., Noll G. Endothelium-dependent vasomotion in aging, hypertension, and heart failure // Circulation 1993. -Vol.87, suppl 7. — P.97−102.
- Luscher Т., Vanhoutte P. The endothelium: modulator of cardiovascular function // Boca Raton. FL: CRC Press 1990. — 215P.
- Luscher T.F. The endothelium and cardiovascular disease a complex relation // N. Engl. J. Med. — 1994. — Vol. 330. — P.1081−1083.
- Luscher T.F., Seo B.G., Buhler F.R. Potential role of endothelin in hypertension. Controversy on endothelin in hypertension // Hypertension -1993.-Vol. 21.-P.752−757.
- Luscher T.F., Tanner F.C., Noll G. Lipids and endothelial function: effects of lipid lowering and therapeutic intervention. // Curr Opin Lipidol 1996- 7: 234−240.
- Luscher TF, Noll G. Is it all in the genes. Nitric oxide synthase and coronary vasospasm. // Circulation 1999−99:2855−7.
- Lusher T.F., Barton M. Biology of the endothelium. // Clin. Cardiol, 1997- 10 (suppl 11), II 3-II-10.
- Lusher T.F., Vanhoutte P.M. The Endothelium: Modulator of Cardiovascular Function. // CRC Press Inc., Boca Raton- 1990:1−228.
- Lusher T.F., Barton M. Biology of the endothelium // Clin. Cardiol. -1997. Vol. 20. — suppl II: II-3-II-10.
- Luzzio G., Biassucci L.M., Gallimore J.R., Gtilli R.L., Rebuzzi A.G., Pepiz M.B., Masera A. Prognostic value of C-reactive protein and serumamyloid A protein in severe unstable angina. I I N. Eng. J. Med.-1994.-Vol. 331.-P. 417−424.
- Mager A, Lalezari S, Shohat T, Birnbaum Y, Adler Y, Magal N, Shohat M. Methylenetetrahydrofolate reductase genotypes and early-onset coronary artery disease.//Circulation. 1999 Dec 14−100(24):2406−10.
- Mancini GBJ, Henry GC, Macaya C. et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dystunc-tion in patients with coronary artery disease, the TREND study. // Circulation, 1996: 94: 258−265.
- Marcovina S.M. and Morrisett J.D. Structure and metabolism of lipoprotein^). // Current Opinion in Lipidology, 6:136−145 (1995).
- Marcovina SM, Koschinsky ML. A critical evaluation of the role of Lp (a) in cardiovascular disease: can Lp (a) be useful in risk assessment? // Semin Vase Med 2002−2:335−44.
- McLenachan JM, Vita J, Fish DR, Teasure CB, Cox DA, Ganz P, Selwyn AP. Early evidence of endothelial vasodilator dysfunction at coronary branching points. // Circulation. 1990−82:1169 -1173.
- McNamara DB, Bedi B, Aurora H et al. L-arginine inhibits balloon catheter-induced intimal hyperplasia. // Biochem. Biophys. Res. Commun. 1993- 1993:291−296.
- Midorikawa S, Sanada H, Hashimoto S, Watanabe T. Enhancement by homocysteine of plasminogen activator inhibitor-1 gene expression and secretion from vascular endothelial and smooth muscle cells.
- Biochem Biophys Res Commun. 2000 May 27−272(1): 182−5.-122 175. Moncada S., Palmer R. M. J., Higgs E. A. Nitric oxide: physiology, pathophysiology, and pharmacology // Pharmacol Rev. 1991. — Vol. 43.-P. 109−142.
- Moncada S., Palmer R.M.J., Higgs E.A. Biosynthesis of nitric oxide from L-arginine: a pathway for the regulation of cell function and communications. // Biochem Pharmacol. 1989- 11:1709−1715
- Motz W, Vogt M, Rabenau O, Scheler S, Luckhoff A, Strauer BE. Evidence of endothelial dysfunction in coronary resistance vessels in patients with angina pectoris and normal coronary angiograms. // Am J Cardiol. 1991 Oct 15−68(10):996−1003.
- Mulder HJ, van Geel PP, Schalij MJ, van Gilst WH, Zwinderman AH, Bruschke AV- PREFACE trial. DD ACE gene polymorphism is associated with increased coronary artery endothelial dysfunction: the PREFACE trial. // Heart. 2003 May-89(5):557−8
- Napoli C, de Nigris F, Palinski W. Multiple role of reactive oxygen species in the arterial wall. // J Cell Biochem. 2001−82:674 -682.
- Park KW, You KH, Oh S, Chae IH, Kim HS, Oh BH, Lee MM, Park YB. Association of endothelial constitutive nitric oxide synthase gene polymorphism with acute coronary syndrome in Koreans.//Heart. 2004 Mar-90(3):282−5.
- Pasceri V, Chang J, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. // Circulation. 2001- 103: 25 312 534.
- Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, Schillaci G. Prognostic significance of endothelial dysfunction in hypertensive patients. // Circulation. 2001- 104:191−196.
- Poirier О, Mao C, Mallet C, Nicaud V, Herrmann SM, Evans A, et al. Polymorphisms of the endothelial nitric oxide synthase gene—no consistent association with myocardial infarction in the ECTIM study. // Eur J Clin Invest 1999−29:284−90.
- Porter TR, Sears T, Xie F, Michels A, Mata J, Welsh D, Shurmur S. Intravascular ultrasound study of angiographically mildly diseased coronary arteries. // J Am Coll Cardiol. 1993 Dec-22(7): 1858−65.
- Prasad A, Halcox JPJ, Waclawiw MA, Quyyumi AA. Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis. // J Am Coll Cardiol. 2001 -38:1089 -1095.
- Prasad A, Narayanan S, Husain S, Padder F, Waclawiw M, Epstein N, Quyyumi AA. Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition. // Circulation. 2000−102:35−41.
- Quyyumi A.A., Dakak N, Andrews NP, Gilligan DM, Panza JA, Cannon RO III. /Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. //Circulation. 1995. -Vol. 92. — P. 320 -326.
- Quyyumi AA, Cannon RO III, Panza JA, Diodati JG, Epstein SE. Endothelial dysfunction in patients with chest pain and normal coronary arteries. // Circulation. 1992−86:1864 -1871.
- Ridker P.M. Inflammation, infection and cardiovackular risk: How good in clinical evidence?//Circulation- 1998.-Vol. 98.-P. 1671 -1674.
- Ridker PM et al. Prospective study of endogenous tissue plasminogen activator and risk of stroke. // Lancet 1994−343:940−943.
- Ridker PM, Gaboury CL, Conlin PR et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. // Circulation. 1993- 87: 1969−1973.
- Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. // Circulation. 2001- 103:1813−1818.
- Rigat В., Hubert C., Corvol P., Soubrier F. / PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene //Nucleic. Acid. Res. 1992- 20- 1433.
- Robert M.F., Pharm D., Francesco Cosentino, Ton J. Rabelink. Atherosclerosis and the two faces of endothelial nitric oxide synthase. // Circulation 1998- 97: 108−112.
- Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein С activation by arterial and venous endothelial cells. // Blood. 1990 Feb 15−75(4):895−901.
- Rodgers GM, Kane WH. Activation of endogenous factor V by a homo-cysteine-induced vascular endothelial cell activator. // J Clin Invest. 1986 Jun-77(6): 1909−16.
- Rodriguez J.A. Homocysteine induces tissue inhibitor of metallopro-teinase-1 expression in vascular smooth muscle cells. // Eur Heart J. -1999. -20.-P397.-126 208. Ross R. Atherosclerosis—an inflammatory disease. // N Engl J Med.1999−340:115−126.
- Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. // Nature 1993.- Vol. 362. — P. 801 — 809.
- Ross R., Atherosclerosis: A Defense Mechanism Gone Awry., // American J Path, 14: 987−1002(1993).
- Rossi GP, Cavallin M, Nussdorfer GG, Pessina AC. The endothelin-aldosterone axis and cardiovascular diseases. // J Cardiovasc Pharmacol. 2001 Nov-38 Suppl 2: S49−52.
- Rudic RD, Bucci M, Fulton D, Segal SS, Sessa WC. Temporal events underlying arterial remodeling after chronic flow reduction in mice: correlation of structural changes with a deficit in basal nitric oxide synthesis. // Circ Res. 2000 9−86(11):1160−6.
- Samani N.J., O’Toole L., Martin D., Rai H., Fletcher S., Lodwik D. Insertion/deletion polymorphism in the angiotensin-converting enzyme gene and risk of and prognosis after myocardial infarction. // J. Am. Coll. Cardiol. 1996- 28- PP. 338−344.
- Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. //Circulation. 2000−101:1899−1906.
- Schachter F, Faure-Delanef L, Guenot F, Rouger H, Froguel P, Lesueur-Ginot L, Cohen D: Genetic associations with human longevity at the APOE and ACE loci. // Nat Genet 1994, 6:29−32
- Schuster H, Wienker TF, Stremmler U, Noll B, Steinmetz A, Luft FC: An angiotensin-converting enzyme gene variant is associated with acute myocardial infarction in women but not in men. // Am J Cardiol 1995, 76:601−603
- Seiler C, Kirkeeide RL, Gould KL. Basic structure-function relations of the epicardial coronary vascular tree. Basis of quantitative coronary arteriography for diffuse coronary artery disease. // Circulation. 1992 Jun-85(6): 1987−2003.
- Smith LR, Harrell FE Jr, Rankin JS, Califf RM, Pryor DB, Muhlbaier LH, et al. Determinants of early versus late cardiac death in patients undergoing coronary artery bypass graft surgery. // Circulation 1991−84:245−53.
- Smith P.D., Steeds R., Channer K., Samani N.J. Constitutive endothelial nitric oxide synthase polymorphism and risk of myocardial infarction. // Congress of the European society of Cardiology, 20-th. Barselona 1998- Abstaract: 2063.
- Snyder S.H., Bredt D.S. Biological roles of nitric oxide. // Sci Am 1992. -Vol.266.-P.68−71.
- Staessen J.A., Ginocchio G., Wang J.G., Saavedra A.P., Soubrier F., Vli-etinck R., Fagart R. Genetic variability in the renin- angiotensin system: prevalence of alleles and genotypes. // J. Cardiovasc. Risk 1997- 4 (5−6) PP401−422.
- Stefansson S., Haudenschild C.C., Lawrence D.A. Beyond fibrinolisis: the role of plasminogen activator inhibitor and vitronectin in vascular wound healing. // Trends Cardiovasc. Med. 1998. — Vol.8. — P.175- 180.
- Suwaidi JA, Ilamasaki S, Higano ST, et al. Long-term follow-up ofpa-tients with mild coronary artery disease and endothelial dysfunction.// Circulation. 2000- 101:948 -954.
- Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. // Drugs.2002−62:265−284.
- Taddei S., Virdis A., Ghiadoni L. et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. // Circulation 1995- 91: 1981−1987.
- Takase B, Uehata A, Akima T, Nagai T, Nishioka T, Hamabe A, Sato-mura K, Ohsuzu F, Kurita A. Endothelium-dependent flow-mediatedvasodilation in coronary and brachial arteries in suspected coronary artery disease. // Am J Cardiol. 1998−82:1535−1539.
- Ting HH, Timimi FK, Boles KS et al. Vitamin С improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. // J. Clin. Invest. 1996: 97: 22−28.
- Ting HH, Timimi FK, Haley EA, et al. Vitamin С improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. //Circulation. 1997−95:2617−2622.
- Tiret L, Kee F, Poirier O, Nicaud V, Lecerf L, Evans A, Cambou J-P, Arveiler D, Luc G, Amouyel P. Deletion polymorphism in angiotensin-converting enzyme gene associated with parental history of myocardial infarction. // Lancet. 1993−341:1991−1992.
- Tousoulis D., Tentolouris C., Crake T. et al. Basal and flow-mediated nitric oxide production by atheromatous coronary arteries. //J Am Coll Cardiol. 1997- 29: pp. 1256−1262.
- Vane J.R., Anggard E.E., Batting R.M. Regulatory functions of the vascular endotnelium. New England Journal of Medicine, 1990: 323: 27−36.
- Vanhoutte P.M. Endothelial dysfunction and atherosclerosis. //Eur Heart J. 1997- 18(Suppl E): pp. E19-E29.
- Vanhoutte P.M. How to assess endothelial function in human blood vessels.//J Hypertens 1999- 17: 1047−1058.
- Vanhoutte P.M., Boulanger C.M., Mombouli J.V. Endothelium-derived relaxing factors and converting enzyme inhibition. //Am J Cardiol. 1995- 76: pp. 3E-12E.
- Vanhoutte PM, Mombouli JV. Vascular endothelium: vasoactive mediators. // Prog. Cardiovase. Dis., 1996- 39: 229−238.
- Vaughan D.E., Rouleau J-L., Ridker P.M. et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. // Circulation, 1997- 96: 442−447.
- Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expresiion of plasminogen activator inhibitor-1 in cultured endothelial cells. // J. Clin. Invest. 1995- 95: 995−1001.
- Vaughan DE. Endothelial function, fibrinolysis, and angiotensyn-converting enzym inhibition. // Clin. Cardiology. 1997- 20 (SII): II-34-II-37.
- Verma S., Fedak P.W.M., Weisel R.D., Fundamentals of Endothelial Function for the Clinical Cardiologist //Circulation. 2002. Vol.105. -P.546 — 549
- Vogel R.A. Coronary risk factors, endothelial function, and atherosclerosis: a review. // Clin Cardiol 1997- 20: 426−432.
- Vogel RA, Coretti MC, Ploinic GD. Effect of single high-fat meal on endothelial hinction in healthy subject. // Amer. J. Cardiol. 1997- 79: 350 354.
- Vogel RA, Corretti MC. Estrogens, progestins, and heart disease: can endothelial function divine the benefit? // Circulation. 1998−97:1223−1226.
- Vogel RA. Cholesterol lowering and endothelial function. // Am J Med. 1999- 107:479 -487.
- Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. // BMJ. 2002 23−325(7374): 1202.
- Wang H, Yoshizumi M, Lai K, Tsai JC, Perrella MA, Haber E, Lee ME. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. // J Biol Chem. 1997 Oct 3−272(40):25 380−5.
- Wang X.L., Mahaney M.C., Siew A. et al. Genetic Contribution of the Endothelial Constitutive Nitric Oxide Synthase Gene to plasma Nitric Oxide Levels. //Arterioscler Thromb Vase Biol 1997- 17: 3147−3153.
- Wang X.L., Cai H, Cranney G, Wilcken DE. The frequency of a common mutation of the methionine synthase gene in the Australian population and its relation to smoking and coronary artery disease. // J Cardiovasc Risk. 1998 Oct-Dec-5(5−6):289−95.
- West M.J., Summers K.M., Wong K.K., Burstow D.J. Renin-angiotensin system gene polymorphisms and left ventricular hypertrophy. The case against an association. // Adv Exp Med Biol.-1997.-Vol.432.-P.l 17−22.
- Wuyts В., Delanghe J., De Buyzere M. Angiotensin I-converting enzyme insertion/deletion polymorphism: clinical implications. // Acta Clin Belg.-1997.-Vol.52.-P.338−49.
- Xu D., Neville R., Finkel T. Homocysteine accelerates endothelial cell senescence. // FEBS Lett.- 2000.-Vol.470.-P.20−4.
- Yoshimura M., Yasue H., Nakayama M., Shimasaki Y., Sumida H., Sugi-yama S. A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. // Hum Genet.-1998.-Vol. 103 .-P.65−9.
- Zeiher A.M., Fisslthaler В., Schray-Utz B. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. // Circulat Res.- 1995.-Vol.76.-P.980−986.
- Zeiher A.M., Drexeler H., Wollschlyger H., Just H. Modulation of coronary vascular tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. // Circulation-1991-Vol.83-P.391−401.
- Zeiher A.M., Drexler H., Wollschlager H., Just H. Endothelial dysfunction of the coronary micro vasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. // Circulation- 199 l-Vol.84-P. 1984 -1992.
- Zeiher A.M., Krause Т., Schachinger V. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. // Circulation-1995-Vol.91-P. 2345−2352.
- Zeiher A.M., Schachinger V. Long-term cigarette smoking impairs endo-theliu in-dependent coronary arterial vasodilator function. // Circulation-1995-Vol.92-P. 1094−1100-
- Zhang H., Snead C. Nitric oxide differentials regulares induction of type II nitric oxide synthase in rat vascular smooth muscle cells versus macrophages. //Arterioscler. Thromb. Vase. Biol.- 2001-Vol.21-P.529−535.